Sol-Gel Technologies (NASDAQ:SLGL) vs. Collegium Pharmaceutical (NASDAQ:COLL) Head-To-Head Survey

Collegium Pharmaceutical (NASDAQ:COLL) and Sol-Gel Technologies (NASDAQ:SLGL) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

Analyst Ratings

This is a summary of current ratings and recommmendations for Collegium Pharmaceutical and Sol-Gel Technologies, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Collegium Pharmaceutical	0	2	7	1	2.90
Sol-Gel Technologies	1	0	4	2	3.00

Collegium Pharmaceutical presently has a consensus target price of $44.88, suggesting a potential upside of 83.39%. Sol-Gel Technologies has a consensus target price of $197.50, suggesting a potential upside of 221.14%. Given Sol-Gel Technologies’ stronger consensus rating and higher possible upside, analysts clearly believe Sol-Gel Technologies is more favorable than Collegium Pharmaceutical.

Valuation and Earnings

This table compares Collegium Pharmaceutical and Sol-Gel Technologies”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Collegium Pharmaceutical	$815.19 million	0.93	$62.87 million	$1.00	24.47
Sol-Gel Technologies	$1.79 million	112.17	-$6.13 million	($5.64)	-10.90

Collegium Pharmaceutical has higher revenue and earnings than Sol-Gel Technologies. Sol-Gel Technologies is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

26.2% of Sol-Gel Technologies shares are held by institutional investors. 1.8% of Collegium Pharmaceutical shares are held by company insiders. Comparatively, 66.5% of Sol-Gel Technologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Collegium Pharmaceutical and Sol-Gel Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Collegium Pharmaceutical	4.68%	85.14%	13.80%
Sol-Gel Technologies	-910.14%	-44.05%	-36.96%

Volatility & Risk

Collegium Pharmaceutical has a beta of 0.75, meaning that its share price is 25% less volatile than the S&P 500. Comparatively, Sol-Gel Technologies has a beta of 1.25, meaning that its share price is 25% more volatile than the S&P 500.

Summary

Collegium Pharmaceutical beats Sol-Gel Technologies on 8 of the 15 factors compared between the two stocks.

About Collegium Pharmaceutical

Collegium Pharmaceutical is a U.S.-based specialty pharmaceutical company focused on developing and commercializing medicines for pain management. Its portfolio includes Xtampza ER, an extended-release oxycodone product; Belbuca, a buprenorphine buccal film for chronic pain; and Nucynta, tapentadol tablets available in immediate- and extended-release formulations. The company also markets Symproic, a treatment for opioid-induced constipation. Collegium’s products include extended-release and opioid medicines, and the company emphasizes responsible use and risk-mitigation measures in its commercial activities.

About Sol-Gel Technologies

Sol-Gel Technologies Ltd. is a dermatology-focused specialty pharmaceutical company based in Israel. The company develops and commercializes topical prescription medicines for common skin conditions, using proprietary delivery technologies designed to improve the stability, tolerability, and effectiveness of active pharmaceutical ingredients. Its marketed products include Epsolay, a topical benzoyl peroxide cream indicated for the treatment of inflammatory lesions associated with rosacea, and Twyneo, a fixed-dose topical combination of tretinoin and benzoyl peroxide for acne vulgaris.